Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Sponsored by Novartis Vaccines
About this trial
Last updated 8 years ago
Study ID
V59P22E1
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
22 to 45 Years
All Sexes
Trial Timing
Ended 15 years ago
What is this trial about?
The primary purpose of this study is to evaluate the persistence of bactericidal antibodies in children of approximately 22 to 45 months of age previously enrolled in the V59P22 study (NCT00667602) who received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine. This is measured by percentage of subjects with human Serum Bactericidal Assay (hSBA) titers ≥ 1:8 directed against Neisseria meningitidis serogroups A, C, W-135, and Y. In addition the response one month post an additional dose of Novartis MenACWY will be measured by percentage of subjects with hSBA titers ≥ 1:8 and GMTs.
What are the participation requirements?
Inclusion Criteria
Children eligible to be enrolled in the study were those
* whose parents provide written informed consent;
* were in generally good health based on the clinical judgment of the investigators;
* subjects were 22-45 months of age at the time of enrollment into V59P22E1;
* subject who had participated in the parent V59P22 study.
Exclusion Criteria
Main exclusion criteria:
* Subjects with serious, acute, or chronic illnesses
* Subjects who had received any other licensed vaccines within 28 days (Exception: Influenza vaccine was allowed up to 14 days prior to and no less than 14 days after the study immunization) prior to enrolment and any study visit
* Subjects who had received any Meningococcal vaccine since the study dose of MenACWY or Men C at 12 months of age in V59P22 trial.